RxDoctor Payments Data

Brion Winston, MD

Cardiovascular Disease · Albany, NYNPI 1932201159

Payments from drug & device makers

$105,285in general payments, 2019–2025

Across 579 payments — averaging $181.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$72K
  • Angiodynamics, Inc.$15K
  • Edwards Lifesciences$11K
  • Inari Medical, Inc.$3K
  • Abbott$1K
  • Novartis$653
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$18,86618%
  • Speaking & faculty fees$58,60056%
  • Travel & lodging$17,31816%
  • Food & beverage$10,40010%
  • Education$1010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,285 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$839,883
Medicare patients
911
Services billed
12,420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban293$400,764
VyndaqelTafamidis Meglumine12$241,989
EntrestoSacubitril/Valsartan109$173,188
JardianceEmpagliflozin121$168,536
XareltoRivaroxaban60$89,498
Repatha SureclickEvolocumab67$57,752
WegovySemaglutide23$42,831
BrilintaTicagrelor23$29,191
MounjaroTirzepatide27$28,119
OzempicSemaglutide30$27,912
FarxigaDapagliflozin Propanediol24$23,597
Atorvastatin Calcium947$11,318
Praluent PenAlirocumab17$10,512
Ranolazine ErRanolazine86$8,516
ClopidogrelClopidogrel Bisulfate527$6,333

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndaqel$302$642,752305 claims
NovartisEntresto$653$173,188109 claims
Boehringer IngelheimJardiance$153$168,536121 claims
Johnson & JohnsonXarelto$214$89,49860 claims
Novo NordiskWegovy, Ozempic$20$70,74353 claims
AstraZenecaBrilinta, Farxiga$80$52,78847 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →